

Updated DuPont Business Reporting Segments

Supplemental slides in conjunction with DuPont press release issued on February 1, 2021: **“DuPont Positioned as a Premier Multi-industrial Company Equipped for Growth and Value Creation, following Completion of IFF and Nutrition & Biosciences Merger”**

February 1, 2021



Updated business reporting segments

FROM

Electronics & Imaging		
Image Solutions	Interconnect Solutions	Semiconductor Technologies
Transportation & Industrial		
Healthcare & Specialty	Industrial & Consumer	Mobility Solutions
Safety & Construction		
Safety Solutions	Shelter Solutions	Water Solutions
Non-Core*		

Businesses that are shifting to Electronics & Industrial

- ✓ Kalrez® materials/ Vespel® parts and shapes
- ✓ MOLYKOTE® lubricants
- ✓ Liveo™ healthcare silicones

Businesses that are shifting to Mobility & Materials

- ✓ Microcircuit Materials
- ✓ Tedlar® materials
- ✓ DuPont Teijin Films JV

TO

Electronics & Industrial		
Industrial Solutions	Interconnect Solutions	Semiconductor Technologies
Mobility & Materials		
Advanced Solutions	Engineering Polymers	Performance Resins
Water & Protection		
Safety Solutions	Shelter Solutions	Water Solutions



*Biomaterials, Clean Technologies and Solamet to be aligned to Corporate

Premier multi-industrial with market-leading businesses

Pro forma net sales*



Electronics & Industrial

- › Industrial Solutions
- › Interconnect Solutions
- › Semiconductor Technologies

~\$4.7B



Water & Protection

- › Safety Solutions
- › Shelter Solutions
- › Water Solutions

~\$5B



Mobility & Materials

- › Advanced Solutions
- › Engineering Polymers
- › Performance Resins

~\$4B

**Represents preliminary pro forma 2020 net sales derived from the Company's preliminary results announced on January 26, 2021. Approximately \$0.6B of preliminary 2020 net sales currently in Non-Core will be realigned to Corporate.*



Cautionary Statement Regarding Forward Looking Statements

This communication contains "forward-looking statements" within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as "expect," "anticipate," "intend," "plan," "believe," "seek," "see," "will," "would," "target," and similar expressions and variations or negatives of these words.

Effective August 31, 2017, E. I. du Pont de Nemours ("EID") and The Dow Chemical Company ("TDCC") each merged with subsidiaries of DowDuPont Inc. (n/k/a "DuPont") and, as a result, EID and TDCC became subsidiaries of the Company. On April 1, 2019, the Company completed the separation of the materials science business through the spin-off of Dow Inc., ("Dow") including Dow's subsidiary TDCC, (the "Dow Distribution"). On June 1, 2019, the Company completed the separation of the agriculture business through the spin-off of Corteva, Inc. ("Corteva") including Corteva's subsidiary EID, (the "Corteva Distribution and together with the Dow Distribution, the "DWDP Distributions").

February 1, 2021 is the completion date of the Company's divestiture of the Nutrition & Biosciences ("N&B") business to IFF in a Reverse Morris Trust transaction (the "N&B Transaction") that resulting in IFF issuing shares to DuPont stockholders.

Forward-looking statements address matters that are, to varying degrees, uncertain and subject to risks, uncertainties and assumptions, many of which that are beyond DuPont's control, that could cause actual results to differ materially from those expressed in any forward-looking statements. Forward-looking statements are not guarantees of future results and include statements about preliminary results for 2020. DuPont's financial closing procedures for the quarter and year ended December 31, 2020 are not yet complete. As a result, it is possible that the Company's actual results may differ from these estimates due to the completion of financial closing procedures and/or any developments that may arise between now and the time the financial results for the fourth quarter and year-end 2020 are finalized. Some of other important factors that could cause DuPont's actual results to differ materially from those projected in any such forward-looking statements include, but are not limited to: (i) failure to obtain anticipated tax treatment and changes in relevant tax or other laws related to the N&B Transaction; (ii) the possibility that unforeseen liabilities, future capital expenditures, revenues, expenses, earnings, synergies, economic performance, indebtedness, financial condition, losses, future prospects, business and management strategies could impact the value to DuPont stockholders of the N&B Transaction; (iii) risks and costs related to potential liability arising from fraudulent conveyance and similar laws in connection with the N&B Transaction and or the DWDP Distributions; (iv) risks and costs related to the Corteva Distribution including indemnification of certain legacy liabilities of EID and failure to effectively manage acquisitions, divestitures, alliances, joint ventures and other portfolio changes, including meeting conditions under the Letter Agreement, entered in connection with the Corteva Distribution, related to the transfer of certain levels of assets and businesses; (v) uncertainty as to the long-term value of DuPont common stock; (vi) potential inability or reduced access to the capital markets or increased cost of borrowings, including as a result of a credit rating downgrade (vii) risks and uncertainties related to the novel coronavirus (COVID-19) and the responses thereto (such as voluntary and in some cases, mandatory quarantines as well as shut downs and other restrictions on travel and commercial, social and other activities) on DuPont's business, results of operations, access to sources of liquidity and financial condition which depend on highly uncertain and unpredictable future developments, including, but not limited to, the duration and spread of the COVID-19 outbreak, its severity, the actions to contain the virus or treat its impact, and how quickly and to what extent normal economic and operating conditions resume; (viii) risks and costs related to the performance under and impact of the cost sharing arrangement by and between DuPont, Corteva, EID and Chemours related to future eligible PFAS liabilities; and (ix) other risks to DuPont's business, operations and results of operations discussed in DuPont's annual report on Form 10-K for the year ended December 31, 2019 and its subsequent reports on Form 10-Q and Form 8-K. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on DuPont's consolidated financial condition, results of operations, credit rating or liquidity. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. DuPont assumes no obligation to publicly provide revisions or updates to any forward-looking statements whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws.





© 2021 DuPont de Nemours, Inc. All rights reserved.

DuPont™, the DuPont Oval Logo, and all products, unless otherwise noted, denoted with ™, SM or ® are trademarks, service marks or registered trademarks of affiliates of DuPont de Nemours, Inc.